- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Advances in Multiple Sclerosis
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-06-03
DOI
10.3389/fneur.2022.824926
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis
- (2021) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
- Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes
- (2021) Michael Hecker et al. MOLECULAR NEUROBIOLOGY
- Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
- (2021) Emanuele D’Amico et al. Neurotherapeutics
- Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis
- (2021) Hans-Peter Hartung et al. CURRENT OPINION IN NEUROLOGY
- Treatment of Women with Multiple Sclerosis Planning Pregnancy
- (2021) Kristen M. Krysko et al. Current Treatment Options in Neurology
- Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
- (2021) Aurora Zanghì et al. Neurotherapeutics
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
- (2021) Ludwig Kappos et al. JAMA Neurology
- Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
- (2021) Daniel S Reich et al. LANCET NEUROLOGY
- Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results
- (2021) Ralf Gold et al. Multiple Sclerosis Journal
- B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
- (2021) Maria T. Cencioni et al. Nature Reviews Neurology
- Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
- (2021) Stephen L Hauser et al. NEUROLOGY
- What telomeres teach us about MS
- (2021) Annalise E. Miner et al. Multiple Sclerosis and Related Disorders
- Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis
- (2021) Anthony T Reder et al. Multiple Sclerosis and Related Disorders
- T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis
- (2021) Carolina Cruciani et al. Neurology-Neuroimmunology & Neuroinflammation
- Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial
- (2021) Tanuja Chitnis et al. LANCET NEUROLOGY
- Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
- (2021) Jue Hou et al. JAMA Network Open
- Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
- (2020) Robert T. Naismith et al. CNS DRUGS
- Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
- (2020) Jeremy Chataway et al. LANCET NEUROLOGY
- N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study
- (2020) Daniel A. Monti et al. Frontiers in Neurology
- T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis
- (2020) Martina Kunkl et al. Cells
- Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis
- (2020) Kristen M. Krysko et al. ANNALS OF NEUROLOGY
- Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations
- (2020) Mark S. Freedman et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Association between shorter leukocyte telomeres and multiple sclerosis
- (2020) Raneem Habib et al. JOURNAL OF NEUROIMMUNOLOGY
- Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
- (2020) Helmut Butzkueven et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
- (2020) Anna He et al. LANCET NEUROLOGY
- The 2013 clinical course descriptors for multiple sclerosis
- (2020) Fred D. Lublin et al. NEUROLOGY
- Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
- (2020) Tjalf Ziemssen et al. CNS DRUGS
- The window of opportunity for treatment of progressive multiple sclerosis
- (2020) Per Soelberg Sorensen et al. CURRENT OPINION IN NEUROLOGY
- Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
- (2020) Wendy Gilmore et al. Journal of Neuroinflammation
- Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis
- (2020) Emanuele D’Amico et al. JOURNAL OF NEUROLOGY
- Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab
- (2020) Chiara Rosa Mancinelli et al. Multiple Sclerosis Journal
- Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
- (2020) Stephen L. Hauser et al. NEUROLOGY
- Ofatumumab versus Teriflunomide in Multiple Sclerosis
- (2020) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of B cells in Multiple Sclerosis and related disorders
- (2020) Giancarlo Comi et al. ANNALS OF NEUROLOGY
- Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Bruce A C Cree et al. LANCET NEUROLOGY
- The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
- (2020) David Baker et al. Multiple Sclerosis and Related Disorders
- Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
- (2020) Despoina Florou et al. Brain Sciences
- Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
- (2020) Jerry S Wolinsky et al. LANCET NEUROLOGY
- The spectrum of progressive multifocal leukoencephalopathy: A practical approach
- (2019) Thorsten Bartsch et al. EUROPEAN JOURNAL OF NEUROLOGY
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
- (2019) J. William L. Brown et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis
- (2019) Richard K. Burt et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
- (2019) Katharine Harding et al. JAMA Neurology
- The prevalence of MS in the United States
- (2019) Mitchell T. Wallin et al. NEUROLOGY
- Comparative effectiveness of teriflunomide and dimethyl fumarate
- (2019) Mathias Due Buron et al. NEUROLOGY
- Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation
- (2019) Jeffrey A. Cohen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Paediatric multiple sclerosis: a new era in diagnosis and treatment
- (2019) Sophie Duignan et al. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
- Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
- (2019) Philipp Haselmayer et al. JOURNAL OF IMMUNOLOGY
- Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis
- (2019) Huihui Li et al. JOURNAL OF NEUROLOGY
- Clinical trials of disease-modifying agents in pediatric MS
- (2019) Emmanuelle Waubant et al. NEUROLOGY
- Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
- (2019) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence
- (2019) Martin Diebold et al. Multiple Sclerosis Journal
- Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
- (2019) David-Axel Laplaud et al. NEUROLOGY
- Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
- (2019) Lana Zhovtis Ryerson et al. NEUROLOGY
- Environmental and genetic risk factors for MS: an integrated review
- (2019) Emmanuelle Waubant et al. Annals of Clinical and Translational Neurology
- Telomere Length Is Associated with Disability Progression in Multiple Sclerosis
- (2019) Kristen M. Krysko et al. ANNALS OF NEUROLOGY
- Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells
- (2019) Björn Neumann et al. Cell Stem Cell
- Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis
- (2019) Anastasie M. Dunn-Pirio et al. Current Treatment Options in Neurology
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
- (2019) Giancarlo Comi et al. LANCET NEUROLOGY
- Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
- (2019) Robert T Naismith et al. Multiple Sclerosis Journal
- Vitamin D and MRI measures in progressive multiple sclerosis
- (2019) Justin R. Abbatemarco et al. Multiple Sclerosis and Related Disorders
- Early versus later treatment start in multiple sclerosis: a register-based cohort study
- (2018) T. A. Chalmer et al. EUROPEAN JOURNAL OF NEUROLOGY
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
- (2018) Raju Kapoor et al. LANCET NEUROLOGY
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60
- (2018) Le H Hua et al. Multiple Sclerosis Journal
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis
- (2018) Amit Bar-Or et al. NEUROLOGY
- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis
- (2018) Alexander Rae-Grant et al. NEUROLOGY
- Progressive multifocal leukoencephalopathy after fingolimod treatment
- (2018) Joseph R. Berger et al. NEUROLOGY
- Multiple Sclerosis
- (2018) Daniel S. Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS)
- (2018) Raed Alroughani et al. PEDIATRIC NEUROLOGY
- Interferon β for Multiple Sclerosis
- (2018) Dejan Jakimovski et al. Cold Spring Harbor Perspectives in Medicine
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
- (2018) Mathias Granqvist et al. JAMA Neurology
- Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60
- (2018) Le H Hua et al. Multiple Sclerosis Journal
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis
- (2018) Y. Naegelin et al. Multiple Sclerosis and Related Disorders
- Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
- (2018) Tanuja Chitnis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience
- (2018) E. D’Amico et al. JOURNAL OF NEUROLOGY
- Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
- (2017) Ari J Green et al. LANCET
- Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2017) Valery L Feigin et al. LANCET NEUROLOGY
- Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification
- (2017) Kalliopi Pitarokoili et al. Nature Reviews Neurology
- Autologous hematopoietic stem cell transplantation in multiple sclerosis
- (2017) Maria Pia Sormani et al. NEUROLOGY
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
- (2017) David Baker et al. JAMA Neurology
- Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
- (2017) Ann Marie Weideman et al. Frontiers in Neurology
- Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
- (2017) David Baker et al. EBioMedicine
- Progressive multiple sclerosis: from pathogenic mechanisms to treatment
- (2016) Jorge Correale et al. BRAIN
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Long-term safety and efficacy of teriflunomide
- (2016) Paul O'Connor et al. NEUROLOGY
- Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update
- (2016) Kassandra Munger et al. SEMINARS IN NEUROLOGY
- Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
- (2016) Stacy Ellen Hatcher et al. JAMA Neurology
- Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
- (2015) Adnan M. Subei et al. CNS DRUGS
- Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
- (2015) Ludwig Kappos et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Pathological mechanisms in progressive multiple sclerosis
- (2015) Don H Mahad et al. LANCET NEUROLOGY
- Role of the innate and adaptive immune responses in the course of multiple sclerosis
- (2015) Bernhard Hemmer et al. LANCET NEUROLOGY
- A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis
- (2015) J Kuhle et al. Multiple Sclerosis Journal
- Switching from natalizumab to fingolimod
- (2015) Ludwig Kappos et al. NEUROLOGY
- Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial
- (2015) G. L. Mancardi et al. NEUROLOGY
- Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review
- (2015) Kyla A. McKay et al. Biomed Research International
- A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis
- (2015) J Kuhle et al. Multiple Sclerosis Journal
- B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation
- (2015) Laure Michel et al. Frontiers in Immunology
- Mechanisms of white matter damage in multiple sclerosis
- (2014) Hans Lassmann GLIA
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis
- (2014) Michael P Pender et al. Multiple Sclerosis Journal
- Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis
- (2014) Tomas Kalincik et al. Multiple Sclerosis Journal
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression
- (2014) Alberto Ascherio et al. JAMA Neurology
- Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis
- (2013) Sofia V. Abrahamsson et al. BRAIN
- Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis
- (2013) Marco A. Zarbin et al. OPHTHALMOLOGY
- Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica
- (2013) Jennifer Graves et al. Multiple Sclerosis and Related Disorders
- Meningeal and cortical grey matter pathology in multiple sclerosis
- (2012) Bogdan F Gh Popescu et al. BMC Neurology
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond
- (2011) Markus Kipp et al. Multiple Sclerosis and Related Disorders
- Phase III dose-comparison study of glatiramer acetate for multiple sclerosis
- (2010) Giancarlo Comi et al. ANNALS OF NEUROLOGY
- Safety and efficacy of natalizumab in children with multiple sclerosis
- (2010) A. Ghezzi et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis
- (2009) Mark P. Gorman et al. ARCHIVES OF NEUROLOGY
- IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
- (2009) Joanne L. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study
- (2009) Richard K Burt et al. LANCET NEUROLOGY
- Interferon- mechanisms of action in multiple sclerosis
- (2009) S. Dhib-Jalbut et al. NEUROLOGY
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started